PROCESS FOR THE PREPARATION OF STABLE CRYSTALLINE FORM-I OF LINEZOLID, SUBSTANTIALLY FREE OF RESIDUAL SOLVENT
申请人:Jubilant Life Sciences Limited
公开号:US20150025236A1
公开(公告)日:2015-01-22
The invention relates to a substantially pure linezolid hydroxide having R-isomer content more than about 99.9% relative to its S-isomer. Further aspect of invention provides the ambient moisture condition, which is critical for enantiomeric pure linezolid hydroxide. The obtained substantially enantiomerically pure linezolid hydroxide compound of formula-II can be subsequently converted into the linezolid compound of formula-I, having S-isomer content more than 99.9% relative to R-isomer. Further the invention provides an improved process for preparation of enantiomeric pure linezolid Form-I, wherein linezolid Form-I having the purity more than 99.9% relative to any other known polymorphic form of linezolid. The obtained enantiomeric pure linezolid Form-I can be subsequently converted into the other known polymorphic forms linezolid. The invention also provides stable and substantially solvent-free crystal of Form-I of linezolid.
该发明涉及一种基本纯的利奈唑酮羟化物,其R-异构体含量相对于其S-异构体大约为99.9%以上。发明的另一个方面提供了环境湿度条件,这对于手性纯的利奈唑酮羟化物至关重要。根据公式-II获得的基本手性纯的利奈唑酮羟化合物随后可以转化为具有相对于R-异构体大约为99.9%以上的S-异构体含量的利奈唑酮化合物,即公式-I。此外,该发明提供了一种改进的制备手性纯的利奈唑酮I型的工艺,其中利奈唑酮I型的纯度相对于任何其他已知的利奈唑酮多晶形式均超过99.9%。获得的手性纯的利奈唑酮I型随后可以转化为其他已知的利奈唑酮多晶形式。该发明还提供了利奈唑酮I型的稳定且基本无溶剂的晶体。